Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation

QJM: An International Journal of Medicine

Volumn 105, Issue 10, 2012, Pages 949-957

  Testa, L ^a,b   Agnifili, M ^a   Latini, R A ^a   Mattioli, R ^a   Lanotte, S ^a   De Marco, F ^c   Oreglia, J ^c   Latib, A ^d   Pizzocri, S ^a   Laudisa, M L ^a   Brambilla, N ^a   Bedogni, F ^a,b  

^a S Ambrogio Clinical Institute   (Italy)

^b Department of Cardiac Surgery   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ARTICLE; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FATALITY; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION;

EID: 84867124493     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs114     Document Type: Article

References (26)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation, a meta-analysis. Ann Intern Med 1999, 131, 492-501.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke, the Framingham Study. Stroke 1991, 22, 983-8.
3. Testa L, Andreotti F, Biondi Zoccai GGL, Burzotta F, Bellocci F, Crea F. Ximelagatran/melagatran against conventional anticoagulation, a meta-analysis based on 22639 patients. Int J Cardiol 2007, 122, 117-24.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361, 1139-51.
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365, 883-91.
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365, 981-92.
7. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50, 683-91.
8. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions, empirical evidence from published meta-analysis. BMJ 2003, 326, 472.
9. Testa L, Biondi Zoccai G, Porto I, Trotta G, Agostoni P, Andreotti F, et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 vs. aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 2007, 99, 1637-42.
10. Biondi Zoccai GGL, Lotrionte M, Agostani P, Abbate A, Romagnoli E, Sangiorgi G, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Intern J Cardiol 2011, 150, 325-31.
11. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011; [www .cochrane-handbook.org] Accessed on 2 October 2011.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions, explanation and elaboration. BMJ 2009, 339, b2700.
13. Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005, 34, 224-5.
14. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation, a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57, e101-98.
15. http://www.ema.europa.eu/docs/en_GB/document_library/ Summary_of_opinion/human/000829/WC500105283.pdf (10 April 2012, date last accessed).
16. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022512s000ltr.pdf (10 April 2012, date last accessed).
17. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.html (10 April 2012, date last accessed).
18. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011, 154, 1-11.
19. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation a meta-analysis. Arch Intern Med 2012, 172, 623-31.
20. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010, 363, 1875-6.
21. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012, 172, 397-402.
22. Potpara TS, Lip GYH. New anticoagulation drugs for atrial fibrillation. Clin Pharmacol Therapeut 2011, 90, 502-6.
23. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate, a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124, 1573-9.
24. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation, design and rationale for the effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160, 635-41.
25. Jacobshagen C, Westermann D, Holubarsch C, Böhm M. Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010, ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more. Clin Res Cardiol 2010, 99, 337-44.
26. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008, 61, 455-63.